Shares of Northwest Biotherapeutics (NWBO) are suffering, off 7% in premarket action.
Not helping the cause is TheStreet's Adam Feuerstein, who says DCVax "will fail just like ICT-107 failed because dendritic cancer vaccines are too weak to overcome cancer's innate ability to overpower or evade the body's immune system."
The thrust of the argument here is that positive data from early studies of the DCVax were misleading because the 20 brain cancer patients "were handpicked for treatment."
Feuerstein says the same was true of a small Phase 1 study of ImmunoCellular's ICT-107, which ended up missing its primary OS endpoint in a larger study (triggering a spectacular sell-off last Wednesday).
Feuerstein is responding to an article by SA contributor Josh Ginsburg who, on Monday, explained why he thinks NWBO "is different."